Glenmark Pharmaceuticals Limited (BOM:532296)
India
· Delayed Price · Currency is INR | Market Cap | 367.07B |
| Revenue (ttm) | 139.61B |
| Net Income (ttm) | -1.76B |
| Shares Out | n/a |
| EPS (ttm) | -6.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.50 (0.19%) |
| Ex-Dividend Date | Sep 13, 2024 |
| Volume | 3,476 |
| Average Volume | 50,068 |
| Open | 1,362.85 |
| Previous Close | 1,369.40 |
| Day's Range | 1,343.75 - 1,385.00 |
| 52-Week Range | 883.50 - 1,830.05 |
| Beta | n/a |
| RSI | 32.84 |
| Earnings Date | Feb 7, 2025 |
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/n... [Read more]
Financial Performance
Financial StatementsNews
Glenmark Pharma shares jump 4% as Q3 revenue jumps 35.1% YoY
Glenmark Pharmaceuticals Ltd shares jumped 4% following the release of its Q3 results. As of 10:14 AM, the shares were trading 3.48% higher at Rs 1,369.15. The company posted a net profit of ₹347.9 cr...
Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution, 0.005% in the U.S
Glenmark Pharmaceuticals Inc., USA (Glenmark) has officially launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) in the United States. This FDA-approved treatment is bioequivalent and therap...
Key Results Today: Glenmark Pharma, ABFRL, GNFC, and Narayana Hrudayalaya among stocks in focus as Q3 results roll in
Several key mid-cap and small-cap companies are set to announce their Q3 FY25 earnings today, drawing investor attention. While no Nifty 50 companies are reporting results, stocks from pharmaceuticals...
Glenmark Pharmaceuticals launches Clindamycin Phosphate Foam, 1% in the US Market
Glenmark Pharmaceuticals Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a dermatological treatment that is bioequivalent and therapeutically equivalent to Evoclin® Foam, 1% by ...
Cosmo, Glenmark secure UK MHRA approval of Winlevi for treatment of acne
Glenmark Pharma and Cosmo receives MHRA approval of Winlevi for treatment of acne
Glenmark Pharmaceuticals and Cosmo Pharmaceuticals N.V. have announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winlevi®, a breakthrough topical treatment fo...
Stocks to watch today on February 10: LIC, M&M, Bharat Electronics, Glenmark, Vedanta, Cipla, NHPC, Oil India & more in focus
The Indian stock market is set to witness key movements on February 10, with several companies announcing their Q3FY25 earnings and significant corporate developments. From Bharat Electronics’ major d...
Pharma stocks: Glenmark up 1.57%, Glaxo gains 1.31%, Mankind Pharma declines 2.84%
The pharmaceutical sector exhibited a mix of gains and losses in early trading. Here’s a detailed overview: Gainers: Glenmark Pharmaceuticals surged +1.57%, trading at ₹1,527.20. GlaxoSmithKline (Glax...
Glenmark Pharmaceuticals shares rise over 2% on U.S. market launch of Vitamin K1 Injectable Emulsion
Glenmark Pharmaceuticals shares surged by over 2% today following the company’s announcement of the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, in the U.S. market thr...
Pharma sector stocks: Biocon (+3.10%), Aurobindo Pharma (+0.48%), Divis Labs (+0.39%) rise; Mankind Pharma (-1.43%) leads losers
Pharma sector stocks witnessed mixed movement in early trade today, with selective buying in mid-cap stocks while large-cap players faced profit booking. Stock Performance (as of 10:28 AM): Biocon: ₹3...
Pharma Sector Stocks: Torrent Pharma (+0.25%) rises; Glenmark (-2.29%), Aurobindo (-2.02%) decline
The pharma sector showed mixed trends during the session as of 12:15 AM. Torrent Pharma was the only gainer, rising ₹8.45 to ₹3,336.30 (+0.25%). Sun Pharma dipped ₹4.95 to ₹1,800.50 (-0.27%), and Dr. ...
Motilal Oswal’s healthcare sector picks: Sun Pharma, IPCA, Mankind, Ajanta, and Glenmark
Motilal Oswal Financial Services has highlighted key stock recommendations in the healthcare sector, projecting strong growth potential for 2024. The focus includes prominent pharmaceutical companies ...
Glenmark shares surge 4% following positive Phase 1 trial results for ISB 2001
Glenmark Pharmaceuticals saw its stock price rise by 4% after Ichnos Glenmark Innovation (IGI) announced promising Phase 1 clinical trial results for ISB 2001, a trispecific antibody designed to treat...
HSBC cuts target price for Glenmark Pharma shares to Rs 1,600 after Q2 results
HSBC has maintained a 'Hold' rating on Glenmark Pharma while trimming its target price to ₹1,600
Glenmark Pharmaceuticals Q2 FY25 Results: Revenue up 5.6% YoY to ₹3,433.80 crore, profit at ₹354.48 crore versus loss of ₹180.30 crore YoY
Glenmark Pharmaceuticals Ltd. reported a 5.6% year-on-year (YoY) increase in revenue from operations for Q2 FY25, reaching ₹3,433.80 crore compared to ₹3,207.38 crore in Q2 FY24. On a quarter-on-quart...
Glenmark Pharma Q2 results: Check share price ahead of Q2 results
Glenmark Pharmaceuticals shares are currently trading at ₹1,553.60, marking an increase of 0.92% as the company gears up to release its second-quarter earnings. With a total market cap of ₹43,840.75 c...
Stocks to Watch Today: Hindustan Aeronautics, Grasim, Hero MotoCorp, Muthoot Finance, Bharat Forge, Glenmark Pharma to announce Q2 results
Several companies are scheduled to announce their Q2 FY25 earnings today. The last traded price (LTP) from yesterday’s closing is provided below for each company, which could influence market reaction...
Glenmark Pharmaceuticals Q2 FY25 Results: Shares fall over 3% ahead of earnings release
Glenmark Pharmaceuticals Ltd shares were trading 3.25% lower at ₹1,525.75 on the NSE as of 11:37 a.m. on November 13, 2024, as investors anticipated the company’s Q2 FY25 results. Expectations for Gle...
Glenmark Pharma shares recover after 10% drop – Here’s what you need to know
Glenmark Pharmaceuticals shares experienced a sharp 10% plunge earlier today, trading at ₹1,634.7. However, the stock has started to show signs of recovery as of 9:29 AM, trading 1.18% lower at ₹1,614...
Glenmark Life Sciences shares jump 3% following ‘Buy’ upgrade by Kotak
Glenmark Life Sciences witnessed a surge of 3.15% in its share price, reaching ₹967.95 as of 11:38 AM on October 28, 2024. The stock saw positive momentum following Kotak’s double upgrade, which moved...